Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors

Por Barlaam, Bernard, Anderton, Judith, Ballard, Peter, Bradbury, Robert H., Hennequin, Laurent F. A., Hickinson, D. Mark, Kettle, Jason G., Kirk, George, Klinowska, Teresa, Lambert-van der Brempt, Christine, Trigwell, Cath, Vincent, John, Ogilvie, Donald
Publicado em 2013

Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia

Por Tron, Adriana E., Belmonte, Matthew A., Adam, Ammar, Aquila, Brian M., Boise, Lawrence H., Chiarparin, Elisabetta, Cidado, Justin, Embrey, Kevin J., Gangl, Eric, Gibbons, Francis D., Gregory, Gareth P., Hargreaves, David, Hendricks, J. Adam, Johannes, Jeffrey W., Johnstone, Ricky W., Kazmirski, Steven L., Kettle, Jason G., Lamb, Michelle L., Matulis, Shannon M., Nooka, Ajay K., Packer, Martin J., Peng, Bo, Rawlins, Philip B., Robbins, Daniel W., Schuller, Alwin G., Su, Nancy, Yang, Wenzhan, Ye, Qing, Zheng, Xiaolan, Secrist, J. Paul, Clark, Edwin A., Wilson, David M., Fawell, Stephen E., Hird, Alexander W.
Publicado no Nat Commun (2018)